肝細胞腫瘤 的英文怎麼說

中文拼音 [gānxìbāozhǒngliú]
肝細胞腫瘤 英文
liver cell tumor
  • 肝 : 名詞（人和高等動物的消化器官之一） liver
  • 細 : 形容詞1 （條狀物橫剖面小） thin; slender 2 （顆粒小） in small particles; fine 3 （音量小） thin ...
  • 胞 : Ⅰ名詞1 （胞衣） afterbirth2 （同一個國家或民族的人） fellow countryman; compatriot Ⅱ形容詞（同胞...
  • 腫 : Ⅰ名詞（隆起處） swelling Ⅱ動詞（突起） swell; be swollen
  • 瘤 : 名詞（瘤子） tumour
  • 細胞 : cell; sytes; bioplast; cella; [口語] gene; [生物學] cellule; cellule cellulli cellulo ; cello ; k...
  • 腫瘤 : tumour; core （綿羊體內的）; neoplasm; phyma
  1. Hepatoma cells are differentiated tumor cells derived from liver.

    肝癌細胞是來自肝臟的分化的腫瘤細胞。
  2. Follicular dendritic cell ( fdc ) tumor of the liver is a recently recognized entity

    摘要肝瀘泡樹枝狀細胞腫瘤是最近認知的疾病。
  3. The malignant cells of this hepatocellular carcinoma ( seen mostly on the right ) are well differentiated and interdigitate with normal, larger hepatocytes ( seen mostly at the left )

    該肝細胞癌的惡性腫瘤細胞（主要位於右方）分化較好，並與較大的正常肝細胞（主要位於左方）相互交錯。
  4. Five analogues and five segments were designed and synthesized by using solid phase synthesis method according to separated papaver somniferum pollen tridecapeptide with antitumor activities as leading peptide. their primary secondary structures in solution were determined by cd spectra and their inhibitive activities to human liver and mammary gland cancer cells were assayed by mtt method. the relationship of structure - activity was studied and discussed

    罌粟花粉十三肽對人肝癌和人乳腺癌腫瘤細胞具有明顯的抑制作用，以其為先導化合物，設計併合成了5個類似物和5個片段，結合cd譜測定的二級結構及它們對人肝癌和人乳腺癌腫瘤細胞的抑制作用測定結果，研究並討論了該肽結構與抗腫瘤活性的關系
  5. As the number of tace procedures increased, several extrahepatic collateral pathways to hepatic tumors are being developed including the right internal mammary artery

    隨著栓塞次數的增加，會形成一些肝外的側枝循環供應腫瘤細胞，內乳動脈是其中的一條。
  6. An interesting abnormality encountered in many types of tumour is the synthesis of substance normally restricted to fetal life, e. g. - fetoprotein ( normally produced by fetal hepatocytes ) by liver cell cancer in the adult

    在許多類型腫瘤中出現一種使人關注的異常，是合成在正常情況下限於胎兒期形成的物質，例如成人肝細胞癌產生甲胎蛋白（在正常情況下，由胎兒肝細胞產生） 。
  7. The hepatic adenoma is on the right and is composed of cells that closely resemble normal hepatocytes, but the neoplastic liver tissue is disorganized hepatocyte cords and does not contain a normal lobular architecture

    右側為肝臟腺瘤，腫瘤細胞類似於正常肝細胞，但腫瘤組織中肝細胞條索排列紊亂，無正常肝小葉結構。
  8. Chemoembolization, radiofrequency ablation and ethanol injection all hae well - documented antitumor actiity ; howeer, there is no high leel eidence that waiting list hcc treatment with these modalities is effectie in achieing any of the three aboe - mentioned aims

    文獻報道栓塞化療、射頻消融和無水酒精注射均有抗腫瘤作用，但是，並沒有很可靠的證據表明用這幾種方法對等待移植的肝細胞肝癌病人進行治療可獲得符合以上三點的療效。
  9. The patient was hospitalized with a one - month history of jaundice, abdominal fullness, and poor appetite

    約有百分之五的肝癌病人會以黃疸癥狀來表現，起因在於癌細胞侵入或腫瘤壓迫膽道系統而造成阻塞性黃疸。
  10. Methods. thirty - eight candidates for lt with hepatitis c virus ( hcv ) cirrhosis and hcc were studied. gene expression ( gexp ) analysis of tumor samples was performed using microarrays

    對于小肝癌（ hcc ）的患者而言，肝移植是一種根治療法。由於缺乏預測進展和復發的腫瘤標志物那些有可能被治療的更高階段的肝細胞癌的患者被拒絕用肝移植療法。
  11. Indication : treatment of acute or chronic viral hepatitis ( type b, c ), herpes zoster, pointed condyloma, viral meningitis ( influenza virus, mumps virus, adenovirus ), hairy cell leukemia, chronic granulocyte leukemia, renal cell carcinoma, kaposi ' s sarcoma, lymphoma, malignant melanoma concerned with aids and other virus and tumor diseases

    ：用於急慢性病毒性肝炎（乙肝、丙肝等） 、帶狀皰疹、尖銳濕疣、病毒性腦膜炎（流感病毒、腮腺炎病毒、腺病毒） 、毛細胞白血病、慢性粒細胞白血病、腎細胞癌、愛滋病相關性卡波濟氏肉瘤、淋巴瘤、惡性黑色素瘤等病毒性及腫瘤性疾病。
  12. The portal venous tumor emboli could further induce intrahepatic tumor cells dissemination and metastasis and thus aggravate the portal hypertension with liver cirrhosis leading to massive bleeding of upper alimentary tract or failure of liver function

    由於門靜脈癌栓可導致腫瘤細胞在肝內播散和轉移，並加重肝硬化患者門脈高壓，從而引起上消化道大出血，甚至導致肝功能衰竭。
  13. Tumor antigens of hepatocellular carcinoma and its specific cellular immunity

    肝癌的腫瘤抗原與特異性細胞免疫
  14. Patients in the control group were treated with comprehensive therapy including symptomatic supportive treatment, antiinfective therapy and artificial liver plasmapheresis etc., while those in the treated group were orally taken szrd additionally. patients condition of sleeping and changes of total bilirubin prothrombin activity, tumor necrosis factor and interleukin1 il1 were observed before and after treatment, and the adverse reactions were observed as well

    對照組採用對癥支持抗感染人工肝血漿置換等綜合治療，治療組在此治療基礎上，加用酸棗仁湯口服治療2周，觀察兩組患者睡眠情況，檢測治療前後血清總膽紅素tbil凝血酶原活動度pta腫瘤壞死因子tnf和白細胞介素1 il1等指標，並觀察藥物的不良反應。
  15. Hcc is a common cause of morbidity and mortality. for patients who are not candidates for curatie surgery, systemic chemotherapy is one of the standard treatments

    肝細胞性肝癌是發病和死亡的常見原因.對于不能手術切除腫瘤的患者，予全身化療是標準治療方案之一
  16. A very rare case of hepatocellular carcinoma ( hcc ) extending within the common bile duct ( cbd ) and left intrahepatic duct ( ihd ) with no detectable primary hepatic tumor in a 52 - year - old taiwanese man is reported

    摘要肝細胞癌（肝癌）是國內惡性腫瘤死因中的第一位，住院的大型肝癌患者常見癥狀包括腹痛、食欲不振、體重減輕、腹脹、全身虛弱、腹部腫塊、發燒等。
  17. Neertheless, particularly in the united states, where continued waiting list priority depends on maintaining hcc within milan criteria, use of nonsurgical hcc treatment will likely continue in an effort to forestall tumor progression and waiting list drop - out

    然而，人們將繼續使用非手術方法治療肝細胞肝癌以阻止病人腫瘤惡化和失去移植機會，在要優先接受肝移植就必須保持肝細胞肝癌符合米蘭標準的美國情況尤為如此。
  18. However, further adjuvant therapies should be investigated to improve the prognosis

    和致命的肝細胞癌預后不同，當前治療此一腫瘤的標準方法是積極手術治療。
  19. The satellite nodules of this hepatocellular carcinoma represent either intrahepatic spread of the tumor or multicentric origin of the tumor

    肝細胞癌的衛星結節為腫瘤的肝內擴散或腫瘤的多中心起源。
  20. It has been suggested that patients with hepatocellular carcinoma ( hcc ) undergoing living donor liver transplantation ( ldlt ) have worse recurrence - free survival compared to deceased donor liver transplantation ( clt ), leading to the hypothesis that short waitlist time or fast - tracking may include more aggressive tumors that would have been selected out by traditionally longer waitlist time

    因有已經提議認為肝細胞癌的患者，接受活體供體肝移植的相對于屍體供體肝移植而言，有更壞的存活期無復發率（即更快的移植后復發率） ，導致了認為可能包括更有侵襲性的腫瘤的患者應該在傳統的長時間等待名單上被挑選出來，以短暫等待時間或者快速示蹤（的方式盡快接受肝移植的）假說。
分享友人
分享到 Line

分享到臉書